You are about to access information on our medicines and medical devices aimed exclusively at healthcare professionals.

By virtue of Spanish Royal Decree 1416/1994 of 25 June regulating the advertising of medicinal products for human use, Spanish Royal Decree 1591/2009 of 16 October regulating medical devices and Law 29/2006 of 26 July on the guarantees and rational use of medicines and health products, in this section Bioiberica can only offer advertising content of prescription medicines to health personnel authorised to prescribe or dispense them.

I am a health professional authorised to prescribe or dispense, or a pharma company professional.

You are here

Women-only clinical study reveals that our Collavant® n2 native (undenatured) type II collagen shows joint health benefits at 40 mg/day in six weeks

8 Apr 2024

Bioiberica proudly presents the latest scientific evidence behind its native (undenatured) type II collagen – Collavant® n2. The women-only study explored the effects of 40 mg/day Collavant n2 supplementation on joint functionality and quality of life in women with knee osteoarthritis (OA). The results confirmed that the ingredient enhanced functionality and joint comfort in just six weeks.[1]This finding adds to the bank of positive clinical evidence behind Collavant n2 in the mobility sphere and illuminates the ingredient’s innovation potential in women’s health products specifically. 


Fresh scientific insights revealed for Collavant® n2

Knee OA involves the gradual degeneration of cartilage, causing joint pain, stiffness and reduced mobility. A randomised controlled clinical trial – published in scientific journal, Wiener klinische Wochenschrift (The Central European Journal of Medicine) – set out to investigate the impact of Motilex Caps® (Apsen Farmaceutica, Brazil) in women with the condition, compared to a control and exercise group. Motilex Caps® is a capsule containing Collavant n2 native (undenatured) type II collagen.* The supplemented group received 40 mg of Collavant n2 once daily for six weeks. The results demonstrated a 44.8% improvement in WOMAC pain score – indicating enhanced joint comfort; greater range of motion (ROM) in the knee; and a 10.4% increase in the distance walked during six minutes without discomfort. These findings affirm that Collavant n2 supplementation contributes to improved functionality and comfort in women with knee OA. Positive results were also observed in the exercise group, highlighting potential benefits of combining supplement and exercise interventions for joint health.


New avenues for innovation in women’s health

Joan Bassa, Human Health Business Unit Director at Bioiberica, comments: “These latest clinical conclusions open up new possibilities for innovation with native (undenatured) type II collagen in women’s health, especially during menopause when joint health problems can become a concern due to oestrogen deficiency. Low-dosage, science-backed ingredients that have been shown to support joint health, like Collavant n2, could therefore help to address the needs of women during this life phase.”

Bassa continues: “We know Collavant n2 can support manufacturers in tapping into the broader trends of healthy ageing, mobility and holistic wellness, and now we look forward to collaborating with new and existing partners to explore formulations geared towards empowering women to lead vibrant and active lives.”      


Backed by 20-plus years’ joint health experience

Collavant n2 is a trusted source of native (undenatured) type II collagen extracted from chicken sternum. To learn more about the cutting-edge science behind the ingredient and how you can partner with Bioiberica to bring next-generation health solutions to the market, visit: Bioiberica’s Branded Ingredients.

*These statements have not been evaluated by competent food authorities. The product is not intended to diagnose, treat, cure or prevent any disease. This information is only for business-to-business use and not meant to be addressed to final consumers.



[1] Santana et al. Wien Klin Wochenschr. 2023 Jun;135(11-12):291-300.